Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miricorilant in antipsychotic-induced weight gain (GRATITUDE)
NCT03818256Phase 2Completed
- Sponsor
- Corcept Therapeutics
- Start
- Dec 2019
- Primary completion
- Jun 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of miricorilant in antipsychotic-induced weight gain (AIWG), sponsored by Corcept Therapeutics. Started Dec 2019; status: completed.
02
Drugs
miricorilant
03
Conditions
antipsychotic-induced weight gain (AIWG)
Beyond the preview
Go deeper on NCT03818256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03818256.